ARTICLE | Top Story
Intercept rises on new acquisition rumors
February 13, 2016 2:58 AM UTC
Hepatology company Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) gained $25.93 (28%) to $120.22 on Friday after media reports again said the company was exploring a sale. The company declined to comment on the rumors.
On Dec. 15, 2015, Intercept rose 17% to $163.22 after reports said multiple companies were considering bids to acquire it (see BioCentury Extra, Dec. 15). ...